Pacific Shuanglin Bio-pharmacy Future Growth
Future criteria checks 2/6
Pacific Shuanglin Bio-pharmacy is forecast to grow earnings and revenue by 16.2% and 16.4% per annum respectively. EPS is expected to grow by 16.1% per annum. Return on equity is forecast to be 10.6% in 3 years.
Key information
16.2%
Earnings growth rate
16.1%
EPS growth rate
Biotechs earnings growth | 34.3% |
Revenue growth rate | 16.4% |
Future return on equity | 10.6% |
Analyst coverage | Low |
Last updated | 11 Jul 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,990 | 1,064 | N/A | 1,066 | 4 |
12/31/2025 | 3,500 | 912 | N/A | 1,029 | 5 |
12/31/2024 | 3,039 | 782 | N/A | 635 | 4 |
3/31/2024 | 2,504 | 678 | 134 | 521 | N/A |
12/31/2023 | 2,329 | 612 | 302 | 679 | N/A |
9/30/2023 | 2,287 | 564 | 38 | 473 | N/A |
6/30/2023 | 2,123 | 509 | 11 | 452 | N/A |
3/31/2023 | 2,166 | 538 | 142 | 553 | N/A |
1/1/2023 | 2,405 | 587 | 146 | 524 | N/A |
9/30/2022 | 2,123 | 437 | 155 | 477 | N/A |
6/30/2022 | 2,172 | 436 | 246 | 532 | N/A |
3/31/2022 | 2,187 | 440 | 118 | 459 | N/A |
1/1/2022 | 1,972 | 391 | 82 | 408 | N/A |
9/30/2021 | 1,730 | 386 | 219 | 465 | N/A |
6/30/2021 | 1,413 | 299 | 198 | 400 | N/A |
3/31/2021 | 1,124 | 217 | 86 | 174 | N/A |
1/1/2021 | 1,050 | 186 | 155 | 195 | N/A |
9/30/2020 | 937 | 137 | -41 | 23 | N/A |
6/30/2020 | 941 | 146 | -10 | 47 | N/A |
3/31/2020 | 949 | 161 | 213 | 255 | N/A |
1/1/2020 | 916 | 160 | 150 | 191 | N/A |
9/30/2019 | 867 | 127 | 131 | 166 | N/A |
6/30/2019 | 835 | 91 | 115 | 152 | N/A |
3/31/2019 | 819 | 76 | 76 | 111 | N/A |
1/1/2019 | 860 | 80 | 82 | 117 | N/A |
9/30/2018 | 805 | 60 | 32 | 66 | N/A |
6/30/2018 | 791 | 44 | 7 | 18 | N/A |
3/31/2018 | 771 | 30 | -33 | 0 | N/A |
12/31/2017 | 685 | 22 | N/A | -15 | N/A |
9/30/2017 | 652 | 34 | N/A | -7 | N/A |
6/30/2017 | 600 | 52 | N/A | -11 | N/A |
3/31/2017 | 530 | 52 | N/A | 1 | N/A |
12/31/2016 | 561 | 50 | N/A | 62 | N/A |
9/30/2016 | 545 | 68 | N/A | 40 | N/A |
6/30/2016 | 527 | 66 | N/A | 50 | N/A |
3/31/2016 | 554 | 81 | N/A | 69 | N/A |
12/31/2015 | 500 | 78 | N/A | 70 | N/A |
9/30/2015 | 568 | 70 | N/A | 119 | N/A |
6/30/2015 | 587 | 75 | N/A | 107 | N/A |
3/31/2015 | 513 | 32 | N/A | 99 | N/A |
12/31/2014 | 489 | 123 | N/A | 77 | N/A |
9/30/2014 | 403 | 105 | N/A | 78 | N/A |
6/30/2014 | 393 | 118 | N/A | 114 | N/A |
3/31/2014 | 444 | 149 | N/A | 83 | N/A |
12/31/2013 | 478 | 70 | N/A | 91 | N/A |
9/30/2013 | 496 | 70 | N/A | 123 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 000403's forecast earnings growth (16.2% per year) is above the savings rate (2.9%).
Earnings vs Market: 000403's earnings (16.2% per year) are forecast to grow slower than the CN market (22.1% per year).
High Growth Earnings: 000403's earnings are forecast to grow, but not significantly.
Revenue vs Market: 000403's revenue (16.4% per year) is forecast to grow faster than the CN market (13.6% per year).
High Growth Revenue: 000403's revenue (16.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 000403's Return on Equity is forecast to be low in 3 years time (10.6%).